|
Laboratory Technician in Tallinn (Estonia) |
|
|
Requirements: This position holder will be responsible for providing key technical input into the development of exosome based ELISA assays for cancer and neurodegenerative diseases diagnosis. Candidate must have strong background in ELISA and proteomic techniques with a strong technical attitude and a creative drive and ability to solve challenging technical issues (troubleshooting). He/she must be skilled in the art of molecular biology and biochemistry, has to be able to work in an organized and methodical manner and provide precise and detailed documentation of all work activities.
Key responsibilities include:
- Assist in the development, standardization and validation of the company’s core product, an ELISA exosome based assay for cancer and neurodegeneration diagnostics.
- Provide assistance and training when required to aid the development of junior technicians.
- Assist in developing innovative solutions to achieve technology milestones and to impact product improvements.
- Support constructive and positive internal communications processes.
- Work cross-functionally with team counterparts to support overall product development, and strategy implementation.
- Maintain consistency, quality, standardization and discipline across product-development experiments.
- Maintain customer focused attitude and keep attention to the needs of laboratories, patients, physicians, regulators and third-party payers.
- Must be able to work with human clinical samples (fluids and tissues).
- Be updated on current scientific literature in the field.
Basic technical skills required:
- strong expertise in ELISA
- strong expertise in tissue culture
- good knowledge of standard lab methods (ELISA, SDS-PAGE, PCR, FACS, Western Blot)
- good knowledge of proteomic methods (MALDI-TOF, 2-Dimensional SDS-PAGE)
A minimum of a Master Degree in molecular biology, biochemistry or relevant fields of study is required for this position. The ideal candidate will have in-depth technical knowledge of the above mentioned techniques and basic techniques normally used in area of proteomic and genomic. Three referees will be required.
Languages: Excellent proficiency in English. Italian is an added value.
Offers: Possibility to work in international and multinational context with world class reputation scientists. Very competitive salary compared with national standards. Salary and other benefits are strictly related to professional skills and achievement of pre-determined objectives and milestones.
Deadline: 30.April 2012
|
|
Last Updated on Monday, 16 April 2012 20:08 |
|
|
HBM wellcomes a new important industrial partner |
|
|
Friday, 10 June 2011 21:26 |
|
In July 2011, a new important Partner joined HBM. Poliedra Sanità SpA, a solid company belonging to the STI Group from Italy (www.grupposti.com), entered HBM acquiring 34% of its capital and icreasing HBM capital to 450.000 euro. Poliedra and the STI Group will provide business management expertise and internationalization, therefore consolidating and strenghthening HBM capacities.
HansaBioMed OU is now by far the biggest and more solid R&D performing Biotech Company in Estonia. |
|
Last Updated on Thursday, 18 August 2011 17:43 |
|
HansaBioMed |
|
|
Wednesday, 30 September 2009 20:11 |
|
Hansabiomed OU (HBM) was established in May 2007 with Estonian and Italian private capitals. The owners of HBM include leading scientists at an international level, the inventors of HBM patents and a high quality management. Our major focus is on translational research in exosome based diagnostics of cancer and neurodegenerative diseases.
Global Strategy HBM performs discovery and pre-clinical development of new diagnostic tools having their main focus on a proprietary exosome based ELISA platform called EXOTEST. HBM is currently testing and validating his EXOTEST platform in different cancers and neurodegenerative diseases including Alzheimer, Parkinson and ALS. Our pipeline also includes newly discovered tumor antigens and targets currently under validation. HBM global strategy is to perform preclinical development in-house and out-license or spinn-out IP to major Pharma Companies or NewCo for clinical development and validation and marketing. In addition to internal research and discovery, HBM also scouts for interesting new ideas in the biomedical field, and considers opportunities for patenting or in-licensing highly innovative research performed by independent academic researchers. Our believe and policy is to invest in brain and innovation, and we devote to this activity the larger part of our financial resources and incomes.
Team and Partners Beside Management, our team today consists of 15 scientists and administrative staff, all of them highly qualified and motivated people. Our labs are located in Tehnopol, the Tallinn Technology Park. We have many Academic and non Academic collaborations with different research groups all over the world.
Antonio Chiesi, MD Founder and CEO |
|
Last Updated on Thursday, 18 August 2011 16:35 |
|
|